Evidence map›Paper›PMID 24279801›Full record

Trial reportAmerican journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons2014

Efficacy and safety of vildagliptin in new-onset diabetes after kidney transplantation--a randomized, double-blind, placebo-controlled trial.

M Haidinger, J Werzowa, M Hecking, M Antlanger, G Stemer, J Pleiner, C Kopecky, J J Kovarik, D Döller, G Pacini and 1 more

2 registry-linked trialsOpen access · bronzeAbstract readClinical Trial, Phase IIRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 34 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed, 4 pooled it
7.1field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06095492 narecruitingstarted 2023, after this paper: background citation

Effect of Empagliflozin Versus Linagliptin on Glycemic Outcomes, Renal Outcomes and Body Composition in Renal Transplant Recipients With Diabetes Mellitus: Randomized Controlled Trial (EmLina Renal Trial)

Ran2023Enrolled200Registered outcomes9Posted comparisons0ConditionsDiabetes Mellitus, Kidney Transplant; ComplicationsArmsempagliflozin 25 mg, Linagliptin
PMID 24344941PMID 31539565PMID 28533501PMID 15882287PMID 30862658PMID 25307034other papers from this trial
Open the trial in the graph
NCT06098625 naunknown statusstarted 2023, after this paper: background citation

Effect of Empagliflozin Versus Linagliptin on Glycemic Outcomes, Renal Outcomes and Body Composition in Renal Transplant Recipients With Diabetes Mellitus: Randomized Controlled Trial

Ran2023Enrolled200Registered outcomes13Posted comparisons0ConditionsDiabetes Mellitus, Kidney Transplant; ComplicationsArmsempagliflozin 25 mg, Linagliptin 5 mg Oral Tablet
PMID 24344941PMID 15882287PMID 25307034PMID 31539565PMID 30862658PMID 28533501other papers from this trial
Open the trial in the graph
3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 4 syntheses or guidelines pooled it, 111 citations in OpenAlex.

  1. American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update.Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · 2022
    Guideline
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Kidney Transplant: More than Immunological Problems.Journal of clinical medicine · 2025
    Review
  6. Article
  7. Review
  8. International consensus on post-transplantation diabetes mellitus.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2024
    Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Diabetes in Kidney Transplantation.Advances in chronic kidney disease · 2021
    Review
  15. Review
  16. Review
  17. Article
  18. Post-Transplantation Diabetes Mellitus.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2020
    Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

M HaidingerClinical Division of Nephrology and Dialysis, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria.
J Werzowa
M Hecking
M Antlanger
G Stemer
J Pleiner
C Kopecky
J J Kovarik
D Döller
G Pacini
M D Säemann
Medical University of Vienna · ATNational Academies of Sciences, Engineering, and Medicine · USVienna General Hospital · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

New-onset diabetes after transplantation (NODAT) is a serious complication after kidney transplantation, but therapeutic strategies remain underexplored. Dipeptidyl peptidase-4 (DPP-4) inhibitors selectively foster insulin secretion without inducing hypoglycemia, which might be advantageous in kidney transplant recipients (KTRs) with NODAT. We conducted a randomized, double-blind, placebo-controlled, phase II trial to assess safety and efficacy of the DPP-4 inhibitor vildagliptin. Intraindividual differences in oral glucose tolerance test (OGTT)-derived 2-h plasma glucose (2HPG) from baseline to 3 months after treatment served as primary endpoint. Among secondary outcomes, we evaluated HbA1c, metabolic and safety parameters, as well as OGTTs at 1 month after drug discontinuation. Of 509 stable KTRs who were screened in our outpatient clinic, 63 (12.4%) had 2HPG ≥ 200 mg/dL, 33 of them were randomized and 32 completed the study. In the vildagliptin group 2HPG and HbA1c were profoundly reduced in comparison to placebo (vildagliptin: 2HPG = 182.7 mg/dL, HbA1c = 6.1%; placebo: 2HPG = 231.2 mg/dL, HbA1c = 6.5%; both p ≤ 0.05), and statistical significance was achieved for the primary endpoint (vildagliptin: 2HPG-difference -73.7 ± 51.3 mg/dL; placebo: -5.7 ± 41.4 mg/dL; p < 0.01). Adverse events were generally mild and occurred at similar rates in both groups. In conclusion, DPP-4 inhibition in KTRs with overt NODAT was safe and efficient, providing a novel treatment alternative for this specific form of diabetes.

Indexed as

AdamantaneAgedBlood GlucoseDiabetes Mellitus, Type 2Dipeptidyl-Peptidase IV InhibitorsDouble-Blind MethodFemaleGlucose Tolerance TestGlycated HemoglobinHumansKidney TransplantationMaleMiddle AgedNitrilesPyrrolidinesVildagliptinAdamantaneBlood GlucoseDipeptidyl-Peptidase IV InhibitorsGlycated HemoglobinNitrilesPyrrolidinesVildagliptinDPP-4 inhibitorkidney transplantationnew-onset diabetes after transplantation (NODAT)posttransplant diabetes mellitustransplant associated hyperglycemia

Identifiers

PMID24279801
OpenAlexW1566154831

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.